A Phase 1, Open-Label Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric pH Modification on the Pharmacokinetics of MLN1117 in Healthy Subjects

Trial Profile

A Phase 1, Open-Label Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric pH Modification on the Pharmacokinetics of MLN1117 in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Mar 2017

At a glance

  • Drugs TAK 117 (Primary) ; Lansoprazole
  • Indications Non-small cell lung cancer; Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Takeda Oncology
  • Most Recent Events

    • 18 Mar 2017 Results assessing relative bioavailability of tablets versus capsules and the effect of dosing conditions on PK variability, presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 06 Dec 2016 Status changed from not yet recruiting to completed.
    • 11 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top